The American Journal of Human Genetics, Volume 94 Supplemental Data

Mutations in QARS, Encoding Glutaminyl-tRNA

Synthetase, Cause Progressive Microcephaly,

Cerebral-Cerebellar Atrophy, and Intractable Seizures

Xiaochang Zhang, Jiqiang Ling, Giulia Barcia, Lili Jing, Jiang Wu, Brenda J. Barry, Ganeshwaran H. Mochida, R. Sean Hill, Jill M. Weimer, Quinn Stein, Annapurna Poduri, Jennifer N. Partlow, Dorothée Ville, Olivier Dulac, Tim W. Yu, Anh-Thu N. Lam, Sarah Servattalab, Jacqueline Rodriguez, Nathalie Boddaert, Arnold Munnich, Laurence Colleaux, Leonard I. Zon, Dieter Söll, Christopher A. Walsh, and Rima Nabbout

| ŗ | .Gly45Val | p.Tyr57His | p.Arg403Trp | p.Arg515Trp |
|-------------------------------|------------|------------|-------------|-------------|
| Consensus | TLGST | LLYGL | TLRMK | DPRLF |
| Identity | | | | |
| | | | | |
| H. sapiens NP_005042 | TLGST | LLYGL | TLRMK | DPRLF |
| P. troglodytes XP_001147632 | TLGST | LLYGL | TLRMK | DPRLF |
| M. mulatta XP_001110256 | TLGST | LLYGL | TLRMK | DPRLF |
| B. taurus NP_001029640 | TLGSS | LLYGL | TLRMK | DPRLF |
| C. lupus XP_533833 | TLGST | LLYGL | TLRMK | DPRLF |
| R. norvegicus NP_001007625 | TLGST | LLYGL | TLRMK | DPRLF |
| M. musculus NP_598555 | ILGST | LLYDL | TLRMK | DPRLF |
| G. gallus NP_001012800 | ALGSG | LLYNA | TLRMK | DPRLF |
| D. rerio ENSDARP60918.4 | QLGSS | LLYSM | TLRMK | DPRLF |
| D. melanogaster [NP_524841 | GSA | LIYHM | TLRMK | DPRLF |
| C. elegans NP_502812 | S G | LLYQL | TLRLK | DPRLF |
| A. gambiae XP_319458 | PGV | LIFQA | TLRMK | DPRLF |
| S. cerevisiae NP_014811 | SDY | | | DPRLF |
| S. pompe NP_596745 | -VGSS | | | DPRLY |
| 0. sativa NP_001054822 | GVS | LLYTV | TLEME | DPRLL |
| A. mailana NP_001185094 | TDG | LLYSV | TERMK | DPRLL |
| E.CONTAAC73774 | | | CLRAK | DPRMP |

Figure S1. Amino acids affected by *QARS* mutations are highly conserved.

All four amino acids affected by human mutations are conserved in vertebrates and plants and two of them (Arg403 and Arg515) are conserved in all species examined.



Figure S2. QARS subcellular localization, and protein levels in individual cell lines.

(A) Double labeling of endogenous QARS proteins with ER (ERp72) and Golgi (RCAS1) markers in Cos7 cells (monkey). Scale bar, 20 μ m.

(B) (Top) Western-blot showing that anti-QARS antibody recognizes QARS protein (green) in human cell lines but not Qars protein in a mouse cell line (Neuro2a), and that QARS protein level is similar among tested control and individual lymphoblastoid cell lines in the supernant. (Bottom) Western-blot showing QARS protein level is low in the insoluble fraction of each lymphoblastoid cell lysate. Total protein lysates from HEK293T (human) and Neuro2a (mouse) represent positive and negative controls. Loading control, anti-αTubulin (red).



Figure S3. Neurogenesis in the brains and eyes are preserved in 2 dpf qars mutants.

(A-C) Immunostaining results of fish brain sections (A) showing neural progenitors (anti-Pax6), mitotic cells (anti-PH3) and postmitotic neurons (anti-HuC/D) display similar patterns in 2 dpf *qars* mutants when compared to their (+/+) and (+/-) siblings. Scale bar, 300 μ m. Bar diagrams (B, C) showing that numbers of mitotic cells (anti-PH3 positive) are largely preserved in the brains and eyes of *qars* mutants when compared to their (+/+) and (+/-) siblings, mean ± SEM values are presented.



Figure S4. Effects of human variants on QARS-ASK1 interaction.

Individual recombinant QARS variant as well as wild-type protein were expressed and immunoprecipitated (mouse anti-Flag, clone M2) from a human cell line (HEK293T). Enrichment of recombinant proteins was confirmed by blotting with a rabbit anti-Flag antibody (red). Weak interactions with endogenous ASK1 (green) are detected for all recombinant QARS proteins.

| Table S1 | . Oligo | names | and | sequences. |
|----------|---------|-------|-----|------------|
|----------|---------|-------|-----|------------|

| Name | Sequence |
|-----------------|--|
| CH87 | 5'-CCATTCTACACCCACCATTTG-3' |
| СН90 | 5'-GGGCTCAGTGTGGATCTTCTT-3' |
| CH91 | 5'-GACTCCCTGTCGCTCTTCAC-3' |
| CH92 | 5'-TGCCTGTGCAGAACTAGGTG-3' |
| СН93 | 5'-CACTGCTGCTCTTTGAGGTG-3' |
| СН94 | 5'-GTGCTCGATGGAGTCACAGA-3' |
| CH184 | 5'-CGGACGTGGTGTCTTCTTTC-3' |
| CH185 | 5'-CCAGTGATCTTGTCAATGGCAG -3' |
| CH186 | 5'-GCTAGCTTGCCAAACCTACAGGT -3' |
| CH188 | 5'-CAGCAGACCCTGGTTTCCACCATTGAC-3' |
| CH189 | 5'-GTCAATGGTGGAAACCAGGGTCTGCTG-3' |
| CH190 | 5'-CGAGGCCACACTATGGATGAAGCTGG-3' |
| CH191 | 5'-CCAGCTTCATCCATAGTGTGGCCTCG-3' |
| | 5'- |
| | ACGGTACCATGGAGCAGAAGCTGATCTCAGAAGAGGACCTG |
| | GACTACAAAGACGATGACGACAAGATGGCGGCTCTAGACTCC |
| CH379 | C-3' |
| CH380 | 5'-ATCTCGAGAGCTCACACCTTTCCTGGGTC-3' |
| CH381 | 5'-CGGGATCCTGTTACATGGCTTGGCCTC-3' |
| CH382 | 5'-GAGGCCAAGCCATGTAACAGGATCCCG-3' |
| CH383 | 5'-CTGGGATGACCCATGGCTCTTTACACTC-3' |
| CH384 | 5'-GAGTGTAAAGAGCCATGGGTCATCCCAG-3' |
| KCNT1-Ex1/2 F | 5'-CATTGGTCAGCGAGTGAA-3' |
| KCNT1-Ex1/2 R | 5'-GAACTGGCAGGACAGGTA-3' |
| KCNT1-Ex16/17 F | 5'-TGGCTCCTGCTTGGTTCC-3' |
| KCNT1-Ex16/17 R | 5'-AAAGTTCAGCATCAGTCA-3' |

| Individual | I-1 | I-2 | II-1 | II-2 |
|---------------|--------------------------|-----------------------|----------------|----------------|
| Gender | Male | Male | Male | Female |
| Year of birth | 2008 | 2009 | 2008 | 2009 |
| Age at most | t most 4 years 3 y | | 4.5 yrs | 15 months |
| recent | | | | |
| assessment | | | | |
| Delivery | Term (38wk) | Term | Term (41wk) | Term |
| Birth Weight | 6.2lb (12%) | 6.8lb (22%) | 6lb (9%) | 6.2lb (12%) |
| Birth Height | 19.75" (50%) | 19.5" (41%) | 20.18" (66%) | 19.29" (42%) |
| Birth Head | 11" (-3.9SD) | 12.25" (-2.1SD) | 13.2" (-1.0SD) | 13.2" (-1.0SD) |
| Circumference | | | | |
| | One have after hirth | First day of life | One have after | One menth ald |
| Seizure Unset | One nour after offun | Flist day of the | birth | One month old |
| Developmental | Profound delays, | Profound delays, no | Lack of visual | Normal tone |
| Features | cortical visual | constipation, can | contact from | and eye |
| | impairment, normal | bubble, nystagmus, | birth. | contact until |
| | hearing, chronic | nutrition by Gtube. | Profound | onset of |
| | tracheomologia | | delay at 4.5 | seizures, then |
| | nossible tanetoretinal | | vears | delays by 15 |
| | degeneration as seen in | | years. | months |
| | Leber's congential | | | |
| | amaurosis, no | | | |
| | meaningful visual | | | |
| | response in either eye, | | | |
| | nutrition by Gtube. | | - | - |
| Muscle tone | Mixed hypotonia and | High tone with brisk | Severe | Severe |
| | hypertonia | reflexes | hypotonia | hypotonia |
| Dysmorphisms | Sloping forenead, | Less of sloping | Coarse facies, | N/A |
| | hypotelorism bilateral | brother has | helix of ear | |
| | epicanthal folds broad | bitemporal | and prominent | |
| | flat nasal bridge, high | narrowing. | upper lip. | |
| | arched palate. At age 5 | epicanthal folds, | | |
| | months skin exam with | hyptelorism, low set | | |
| | slightly raised red rash | and posteriorly | | |
| | across his chest and | rotated ears, broad | | |
| | abdomen. | nasal bridge, high | | |
| | | palate. | | |
| | | Unremarkable skin | | |
| Microcenhaly | -4 8SD at 1.5 months | -5 8SD at 3 months: - | -3SD at 4.5 | -2 5SD at 15 |
| wherecephary | -10.4SD at 21months | 7.8SD at 7 months | years | months |

Table S2. Additional clinical findings and developmental measurements.

| | | Allele Frequency (6503 | Amino acid | | PolyPhen- |
|--------|--------------------|------------------------|------------|------|-----------|
| Person | Position (hg19) | samples in EVS) | change | SIFT | 2 |
| I-3 | chr3: 49141888 C>A | 0 | p.G45V | 0.01 | 1 |
| II-4 | chr3: 49141853 A>G | 0 | p.Y57H | 0.14 | 1 |
| I-4 | chr3: 49137482 G>A | 0 | p.R403W | 0 | 1 |
| II-3 | chr3: 49136848 G>A | 0 | p.R515W | 0 | 1 |

Table S3. S CTU mutations are rare and predicted to cause deleterious amino acid substitutions.

QARS mutations identified in both families were not seen in Exome Variant Server (EVS), and the amino acid substitutions are predicted to be damaging to protein functions by SIFT and PolyPhen-2.